M
Martin Reck
Researcher at Bristol-Myers Squibb
Publications - 5
Citations - 1622
Martin Reck is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 4, co-authored 5 publications receiving 831 citations. Previous affiliations of Martin Reck include University of Hamburg.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D. Hellmann,Luis Paz-Ares,Reyes Bernabe Caro,B. Zurawski,Sang-We Kim,Enric Carcereny Costa,Keunchil Park,A. Alexandru,L. Lupinacci,Emmanuel de la Mora Jimenez,Hiroshi Sakai,Istvan Albert,Alain Vergnenegre,Solange Peters,Konstantinos N. Syrigos,Fabrice Barlesi,Martin Reck,Hossein Borghaei,Julie R. Brahmer,Kenneth J. O'Byrne,William J. Geese,Prabhu Bhagavatheeswaran,Sridhar K. Rabindran,Ravi S. Kasinathan,F. E. Nathan,Suresh S. Ramalingam +25 more
TL;DR: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level.
Journal ArticleDOI
Phase II and III studies with carboplatin in small cell lung cancer.
U. Gatzemeier,U. Gatzemeier,Dieter K. Hossfeld,Dieter K. Hossfeld,R. Neuhauss,R. Neuhauss,Martin Reck,Martin Reck,Wolf Achterrath,Wolf Achterrath,Luigi Lenaz,Luigi Lenaz +11 more
TL;DR: Chemotherapy regimens containing platinum compounds are among the most active in the treatment of SCLC and the use of the new compound carboplatin instead of cisplatin has led to similar or increased remission rates and is preferable because it has fewer side effects.
Journal ArticleDOI
A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies
Chris Twelves,Chris Twelves,Martin Reck,Alan Anthoney,Alan Anthoney,Ulrich Gatzemeier,Stan B. Kaye +6 more
TL;DR: ZD0473 combined with paclitaxel has a manageable tolerability profile and shows some evidence of antitumour activity in patients with NSCLC.
Journal ArticleDOI
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
Edward B. Garon,Giorgio V. Scagliotti,Oliver Gautschi,Martin Reck,Michael Thomas,Lara Iglesias Docampo,Haralabos P. Kalofonos,Joo Hang Kim,Steven Gans,Odd Terje Brustugun,S. V. Orlov,Gebra Cuyun Carter,Annamaria Zimmermann,Ana B Oton,Ekaterine Alexandris,Pablo Lee,Katharina Wolff,Victoria Jennifer Stefaniak,Mark A. Socinski,Maurice Pérol +19 more
TL;DR: It is suggested that second-line ram+doc may be effective regardless of prior treatment with platinum-based chemotherapy plus a taxane, pemetrexed, gemcitabine or bevacizumab, and overall, ram+ doc is clinically beneficial across a wide range of patients with metastatic NSCLC who have progressed after various front-line therapies.
Journal ArticleDOI
Targeting the immune system for management of NSCLC: the revival?
TL;DR: Clinical experience of two types of immunotherapy for lung cancer are reviewed, including vaccines against melanoma-associated antigen 3, mucinous glycoprotein-1, transforming growth factor-beta 2, epidermal growth factor, and, less specifically, whole-tumor cell extracts.